Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798883 | 1.00 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL11680189 | 0.82 | SMN1; SMN2 (0.46) | IDO1SMN1; SMN2KDM4ERAB9AMEN1 | |
| SCHEMBL7004600 | 0.82 | CCNC (0.42) | HDAC3HDAC1HDAC2HDAC6HPGDS | |
| SCHEMBL28788425 | 0.81 | IDO1 (0.41) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL25972203 | 0.81 | GPR119 (0.39) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL28834596 | 0.80 | NLRP3 (0.38) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL12923193 | 0.80 | TSHR (0.44) | HDAC3HDAC1HDAC2HDAC6HPGDS | |
| SCHEMBL4086758 | 0.79 | IDO1 (0.44) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL15568312 | 0.78 | TBXAS1 (0.43) | HDAC3HDAC1HDAC2HDAC6HPGDS | |
| SCHEMBL5552406 | 0.78 | IDO1 (0.38) | HDAC3HDAC1HDAC2HDAC6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119797620-B | Efficient water purifying composite microbial agent and preparation method thereof | 山东得和明兴生物科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119797620-A | Efficient water purifying composite microbial agent and preparation method thereof | 山东得和明兴生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| CN-107207509-B | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10258626-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2019-04-16 | — | — | US | disclosed |
| US-20170151251-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-06-01 | — | — | US | disclosed |
| US-9603854-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-03-28 | — | — | US | disclosed |
| CN-104093398-B | 7 (6 (2 hydroxy propane, 2 base) 3 base of pyridine) 1 ((trans) 4 methoxycyclohexyl) 3,4 dihydro pyrazines simultaneously [2,3 B] pyrazine 2 (1H) ketone, the pharmaceutical composition of its solid form and its using method | 西格诺药品有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-104144930-B | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | 瑟维尔实验室 | 2017-02-22 | — | — | CN | disclosed |
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9120791-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20150051189-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2015-02-19 | — | — | US | disclosed |
| WO-2007014054-A2 | BENZENESULFONAMIDE INHIBITOR OF CCR2 CHEMOKINE RECEPTOR | GLAXO GROUP LIMTED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | HDAC3 1652/4885HDAC1 1702/4885HDAC2 1838/4885 |
| US-10258626-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | IDO1, IDO2, API5 | HDAC3 1652/4885HDAC1 1702/4885HDAC2 1838/4885 |
| US-20150051189-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | HDAC3 1652/4885HDAC1 1702/4885HDAC2 1838/4885 |
| US-20170151251-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | HDAC3 1652/4885HDAC1 1702/4885HDAC2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.